Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZG19018 in KRAS G12C Mutant Advanced Solid Tumors
NCT06237400Phase 2Recruiting
- Sponsor
- Zelgen
- Start
- May 2022
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ocatini in solid tumor, non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) (2 arms), sponsored by Zelgen. Primary endpoints: Dose Limiting Toxicity at 21 days and Objective Response Rate at 24 months. Started May 2022; status: recruiting.
02
Drugs
ocatini
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06237400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06237400.